Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...